so, now we got to 3-2015. I have watched this company for the last year and read all posters on this board. I know that the FUSE is innovative. I heard that management is still figuring their way on. Can someone tell me if this is the right time to join EC or not? Do you think they are going to make it?
If you're a brick layer or garbage collector, I highly recommend staying where you are. This place blows!
No, unless you want your salary cut without warning and told that the variable for the comp plan is amazing so that you can make up that salary cut later in the year. No, unless you want to be micromanaged about demos. No, unless you want to deal with unrealistic quotas for your disposable products. No, unless you want to deal with lack of resources and over promises from senior leadership.
Let me get this right. You read all the posts on this board and you're still asking if now is the right time to join EC? You are hopeless.
I spent two years trying to sell Fuse before I left last year. In my opinion I would stay where you are! Olympus absolutely dominates this market and will continue to do so. If you sick sound you will see deal after deal lost to Olympus while upper management asking you what is wrong with you. Physicians are not that impressed with the Fuse system, yes it is innovative but the ability to see peripherally is not enough for physicians to pull the trigger and buy. It's the entire package that EndoChoice just isn't able to offer: high quality pixel image (olympus image kills EC), 1to1 rotation from control handle to distal end, NBI, effective transfer of images to image management software, brand name and reliability that will take years for EndoChoice to achieve (which frankly they do not have the time to get there). Doctors these days are just looking for a reliable piece of equipment (from Olympus) to churn out 20+ cases a day and call it a day. I don't see the company lasting another year or so. From my knowledge they're so tight on money (since Fuse is not selling) that there's a hiring freeze. Just a few thoughts from someone who was with the company for several years.
No docs are making decision based on NBI. To think this is a deal breaker is laughable at best. You need to check your info bc there is definitely no hiring freeze and not sure if you saw or not, but they just raised another $57M from the VCs last month. I can go on and on and rip your post to shreds, but its not worth it. You couldn't get the job done so you left and the only thing left to do is bad mouth the company. I don't work for this company, but I have been following them as Fuse is the only change from a scope standpoint that has happened in the last several decades. Move on, sir.
MD's are most certainly making decisions on NBI. It is an accurate and proven way to find and detail precancerous lesions. No NBI means you're already a leg down. If you don't work for the company, how do you know they raised 57 million from venture capitalists? Shouldn't the sales of the products, specifically FUSE, not warrant another cash influx from VC's? Where's the profits from FUSE? And, if you truly follow the company, (while, ahem, not working for them) how many FUSE scopes have been sold nationwide? I'm not asking how many scopes were given to facilities and key physicians. I'm asking how many scopes were actually purchased in the US to date? Lastly, your response to the above post has some aggressive and negative annotations in it. If you don't work for EC, why do you care?
Interesting that my opinion means nothing coming from someone who has 'followed' the company but hasn't walked in the shoes of a rep actually in the field selling the equipment. Give me a break you troll! Did I say NBI was the ONLY thing physicians were looking at, NO! It's the entire package as I mentioned above. In any case, go get a job with them if you feel like you're such a hot shot! Lol
Not to disregard the rest of your post, but it is pretty easy to know that they raised another $57 million without working there. All it takes is a Google search to know that they received another round of financing in early March.
